drugset / Trial / NCT02024308
AML1-ETO Acute Myeloid Leukemia With Fludarabine and Cytarabine Chemotherapy
RandomizedParallel-groupOpen-labelTreatment
Summary
The purpose of the study is to determine whether Fludarabine in combination with cytarabine is more effective than high-dose cytarabine in post-remission therapy for patients with AML1-ETO acute myeloid leukemia.
Timeline
- Start
- 2010-11
- Primary completion
- 2015-11
- Completion
- 2016-12
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Cytarabine | Small molecule | 1.4 mg/m2 | Intravenous |
| Subject | Cytarabine | Small molecule | 2000 mg/m2 | Intravenous |
| Subject | Fludarabine | Small molecule | 30 mg/m2 | Intravenous |
| Subject | Fludarabine | Small molecule | 50 mg/m2 | Intravenous |